615 related articles for article (PubMed ID: 33013894)
1.
Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
Front Immunol; 2020; 11():2118. PubMed ID: 33013894
[TBL] [Abstract][Full Text] [Related]
2. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
[TBL] [Abstract][Full Text] [Related]
3. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
4. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
5. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy.
Sánchez Acosta G; Kinaciyan T; Kitzmüller C; Möbs C; Pfützner W; Bohle B
J Allergy Clin Immunol; 2020 Oct; 146(4):894-900.e2. PubMed ID: 32259540
[TBL] [Abstract][Full Text] [Related]
6. Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.
Gadermaier E; Marth K; Lupinek C; Campana R; Hofer G; Blatt K; Smiljkovic D; Roder U; Focke-Tejkl M; Vrtala S; Keller W; Valent P; Valenta R; Flicker S
Allergy; 2018 Jul; 73(7):1425-1435. PubMed ID: 29315611
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules.
Pree I; Shamji MH; Kimber I; Valenta R; Durham SR; Niederberger V
Clin Exp Allergy; 2010 Sep; 40(9):1346-52. PubMed ID: 20604801
[TBL] [Abstract][Full Text] [Related]
8. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
[TBL] [Abstract][Full Text] [Related]
9. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
10. Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1.
Svenson M; Jacobi HH; Bødtger U; Poulsen LK; Rieneck K; Bendtzen K
Mol Immunol; 2003 Jan; 39(10):603-12. PubMed ID: 12431394
[TBL] [Abstract][Full Text] [Related]
11. Natural human Bet v 1-specific IgG antibodies recognize non-conformational epitopes whereas IgE reacts with conformational epitopes.
Brazhnikov G; Smolnikov E; Litovkina A; Jiang T; Shatilov A; Tulaeva I; Tulaev M; Karaulov A; Poroshina A; Zhernov Y; Focke-Tejkl M; Weber M; Akinfenwa O; Elisyutina O; Andreev S; Shilovskiy I; Shershakova N; Smirnov V; Fedenko E; Lepeshkova TS; Beltyukov EC; Naumova VV; Kundi M; Khaitov M; Wiedermann U; Valenta R; Campana R
Allergy; 2023 Dec; 78(12):3136-3153. PubMed ID: 37701941
[TBL] [Abstract][Full Text] [Related]
12. IgE mimotopes of birch pollen allergen Bet v 1 induce blocking IgG in mice.
Ganglberger E; Grünberger K; Wiedermann U; Vermes M; Sponer B; Breiteneder H; Scheiner O; Boltz G; Jensen-Jarolim E
Int Arch Allergy Immunol; 2001; 124(1-3):395-7. PubMed ID: 11307026
[TBL] [Abstract][Full Text] [Related]
13. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
[TBL] [Abstract][Full Text] [Related]
14. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
[TBL] [Abstract][Full Text] [Related]
15. Expression of a human IgG4 antibody, BAB2, with specificity for the major Birch pollen allergen, Bet v 1 in Escherichia coli: recombinant BAB2 Fabs enhance the allergic reaction.
Eibensteiner P; Denépoux S; Steinberger P; Kraft D; Visco V; Banchereau J; Lebecque S; Valenta R
Int Arch Allergy Immunol; 1999; 118(2-4):190-2. PubMed ID: 10224374
[TBL] [Abstract][Full Text] [Related]
16. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
Seutter von Loetzen C; Reuter A; Spiric J; Schulenborg T; Bellinghausen I; Völker E; Vogel L; Rösch P; Schiller D
Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
[TBL] [Abstract][Full Text] [Related]
17. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
[TBL] [Abstract][Full Text] [Related]
18. IgE, IgG4 and IgA specific to Bet v 1-related food allergens do not predict oral allergy syndrome.
Guhsl EE; Hofstetter G; Lengger N; Hemmer W; Ebner C; Fröschl R; Bublin M; Lupinek C; Breiteneder H; Radauer C
Allergy; 2015 Jan; 70(1):59-66. PubMed ID: 25327982
[TBL] [Abstract][Full Text] [Related]
19. An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy.
Selb R; Eckl-Dorna J; Vrtala S; Valenta R; Niederberger V
Allergy; 2013 Sep; 68(9):1199-202. PubMed ID: 23998344
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
